IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer. Issue 8 (6th October 2019)

• Record Type: Journal Article
• Authors: Kruger, Dinja T.; Alexi, Xanthippi; Opdam, Mark; Schuurman, Karianne; Voorwerk, Leonie; Sanders, Joyce; van der Noort, Vincent; Boven, Epie; Zwart, Wilbert; Linn, Sabine C.
• Is Part Of: International journal of cancer. Volume 146:Issue 8(2020)
• Page Start: 2348
• Page End: 2359
• Publication Date: 2019-10-06
• Subjects: breast cancer -- IGF‐1 receptor -- PI3K/MAPK pathway -- adjuvant tamoxifen -- linsitinib; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.32668
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Preclinical studies indicate that activated IGF‐1R can drive endocrine resistance in ER‐positive (ER+) breast cancer, but its clinical relevance is unknown. We studied the effect of IGF‐1R signaling on tamoxifen benefit in patients and we searched for approaches to overcome IGF‐1R‐mediated tamoxifen failure in cell lines. Primary tumor blocks from postmenopausal ER+ breast cancer patients randomized between adjuvant tamoxifen versus nil were recollected. Immunohistochemistry for IGF‐1R, p‐IGF‐1R/InsR, p‐ERα(Ser118), p‐ERα(Ser167) and PI3K/MAPK pathway proteins was performed. Multivariate Cox models were employed to assess tamoxifen efficacy. The association between p‐IGF‐1R/InsR and PI3K/MAPK pathway activation in MCF‐7 and T47D cells was analyzed with Western blots. Cell proliferation experiments were performed under various growth‐stimulating and ‐inhibiting conditions. Patients with ER+, IGF‐1R‐positive breast cancer without p‐IGF‐1R/InsR staining ( n = 242) had tamoxifen benefit (HR 0.41, p = 0.0038), while the results for p‐IGF‐1R/InsR‐positive patients ( n = 125) were not significant (HR 0.95, p = 0.3). High p‐ERα(Ser118) or p‐ERα(Ser167) expression was associated with less tamoxifen benefit. In MCF‐7 cells, IGF‐1R stimulation increased phosphorylation of PI3K/MAPK proteins and ERα(Ser167) regardless of IGF‐1R overexpression. This could be abrogated by the dual IGF‐1R/InsR inhibitor linsitinib, but not by the IGF‐IR‐selective antibody 1H7. In MCF‐7 and T47D cells, stimulation of the IGF‐1R/InsR pathway resulted in cell proliferation regardless of tamoxifen. Abrogation of cell growth was regained by addition of linsitinib. In conclusion, p‐IGF‐1R/InsR positivity in ER+ breast cancer is associated with reduced benefit from adjuvant tamoxifen in postmenopausal patients. In cell lines, stimulation rather than overexpression of IGF‐1R is driving tamoxifen resistance to be abrogated by linsitinib. Abstract : What's new? In breast cancer, the growth factor receptor IGF‐1R is frequently overexpressed, boosting cell proliferation and transformation. Prior work has shown that IGF‐1R pathway activation promotes treatment resistance in cell lines. Here, the authors evaluated whether the pathway contributes to tamoxifen resistance in patients. In patients with ER+ breast cancer, patients whose cancers tested negative for activated IGF‐R1 benefited from adjuvant tamoxifen, while those with cancers tested positive showed little improvement. Next, they showed that treating breast cancer cells with linsitinib can thwart IGF‐1R signaling and restore tamoxifen's efficacy. Patients with activated IGF‐1R pathways may therefore do better with tamoxifen combined with linsitinib than tamoxifen alone.